Article Text

Download PDFPDF

2022-RA-629-ESGO Association of folate receptor α expression and tumor immune microenvironment in patients with cervical cancer
  1. Shu Yazaki1,
  2. Yohei Chiba1,
  3. Yuki Kojima1,
  4. Hiroshi Yoshida2,
  5. Shigemasa Takamizawa1,
  6. Rui Kitadai1,
  7. Ayumi Saito1,
  8. Hitomi Suimyoshi Okuma1,
  9. Tadaaki Nishikawa1,
  10. Tatsunori Shimoi1,
  11. Kazuki Sudo1,
  12. Emi Noguchi1,
  13. Masaya Uno3,
  14. Misuya Ishikawa3,
  15. Tomoyasu Kato3,
  16. Keiji Furuuchi4,
  17. Toshimitsu Uenaka4,
  18. Yasuhiro Fujiwara1 and
  19. Kan Yonemori1
  1. 1Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
  2. 2Diagnostic Pathology, National Cancer Center Hospital, Tokyo, Japan
  3. 3Gynecology, National Cancer Center Hospital, Tokyo, Japan
  4. 4Epochal Precision Anti-Cancer Therapeutics (EPAT), Eisai Inc, Exton, PA


Introduction/Background Folate receptor α (FRα) is an attractive target for cancer treatment based on its expression profile. We previously reported that FRα expression was higher in cervical adenocarcinoma than in squamous cell carcinoma (SCC) and associated with poor survival (Takamizawa et al., AACR 2021). However, the relationship between FRα and the immune microenvironment remains unknown.

Methodology We performed immunohistochemical analysis of whole tumor sections from patients with cervical cancer who underwent primary surgery between 2000 and 2020 at our institution. FRα expression was evaluated using anti-FRα monoclonal antibody clone 26B3. FRα-positive and FRα-high were defined as ≥5% of tumor staining and as H-score ≥60. PD-L1 expression (clone 22C3) was assessed according to the combined positive score (CPS). The density of intratumoral CD3 and CD8 were calculated as the average number of positive cells in the five independent areas. The association between FRα expression and immune biomarkers was analyzed.

Results Overall, 123 patients were evaluated, and 67 were SCC and 56 were non-SCC. FRα-positive and FRα-high were identified in 72.4% and 27.6%. PD-L1 was positive (CPS≥1) in 75.6% and more commonly expressed in SCC (SCC vs. non-SCC; 83.5% vs. 66.1%, p=0.02). FRα expression showed a significantly negative correlation with PD-L1 expression (r=-0.22, p<0.001), and median (IQR) PD-L1 CPS was 20 (5–60) in FRα-negative and 5 (0–25) in FRα-positive group (p=0.04). FRα-positive was more frequent in PD-L1 CPS<10 groups than in PD-L1 CPS≥10 groups (81% vs. 64%, p=0.03). Median CD3 and CD8 counts were not different between FRα-negative and FRα-positive groups.

Conclusion In cervical cancer, FRα expression negatively correlates with PD-L1 expression and is more common in the PD-L1 CPS<10 groups. Our findings suggest that FRα-expression may be a potential therapeutic target for cervical cancer with low/negative PD-L1 expression.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.